1 Introduction
Apatinib, a novel tyrosine kinase inhibitor targeted vascular endothelial growth factor receptor-2 (VEGFR2) for solid tumors, has revealed promising efficacy in treating liver cancer in China. Although it has been reported to have a high incidence of inducing hand-foot skin reactions, other skin adverse reactions induced by apatinib are rare. Herein, we report a rare case of apatinib-induced severe bullous dermatosis that was successfully treated with methylprednisolone and summarize the dermatologic toxicities of VEGFR tyrosine kinase inhibitor.
Key words: tyrosine kinase inhibitor, apatinib, drug adverse reaction, bullous dermatosis